NUDT5 and breast carcinoma: The lead compound TH5427 (Figure 1) was shown to block progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells, suggesting that targeting NUDT5 may represent a novel therapeutic approach for breast cancer treatment.